All lobbying filings

RK STRATEGIES, INC.

RK STRATEGIES, INC. filed a Q2 termination report for ADIAL PHARMACEUTICALS, INC. on July 18, 2026, reporting $10,000 in lobbying income.

Lobbying for ADIAL PHARMACEUTICALS, INC. · Pharmaceutical company

All filings by RK STRATEGIES, INC. · Everything ADIAL PHARMACEUTICALS, INC. has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 18, 2026

Income

$10,000

What the client paid this registrant for the period.

Client based in

Virginia

Representation ended

Jun 30, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

FDA Issues Related to Addiction H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R. 8800, National Defense Authorization Act for Fiscal Year 2027

Defense

FDA Issues Related to Addiction H.R. 7091, Expanding Veterans Access to Emerging Treatments Act H.R. 8800, National Defense Authorization Act for Fiscal Year 2027

Bills named in this filing 2

H.R. 7091
Expanding Veterans’ Access to Emerging Treatments Act
H.R. 8800
National Defense Authorization Act for Fiscal Year 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.